1. Home
  2. YHC vs CING Comparison

YHC vs CING Comparison

Compare YHC & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YHC
  • CING
  • Stock Information
  • Founded
  • YHC 2021
  • CING 2012
  • Country
  • YHC United States
  • CING United States
  • Employees
  • YHC N/A
  • CING N/A
  • Industry
  • YHC Beverages (Production/Distribution)
  • CING Biotechnology: Pharmaceutical Preparations
  • Sector
  • YHC Consumer Staples
  • CING Health Care
  • Exchange
  • YHC Nasdaq
  • CING Nasdaq
  • Market Cap
  • YHC 12.3M
  • CING 14.4M
  • IPO Year
  • YHC N/A
  • CING 2021
  • Fundamental
  • Price
  • YHC $0.83
  • CING $4.56
  • Analyst Decision
  • YHC
  • CING Strong Buy
  • Analyst Count
  • YHC 0
  • CING 3
  • Target Price
  • YHC N/A
  • CING $16.00
  • AVG Volume (30 Days)
  • YHC 54.0K
  • CING 128.4K
  • Earning Date
  • YHC 03-31-2025
  • CING 03-31-2025
  • Dividend Yield
  • YHC N/A
  • CING N/A
  • EPS Growth
  • YHC N/A
  • CING N/A
  • EPS
  • YHC N/A
  • CING N/A
  • Revenue
  • YHC $2,272,001.00
  • CING N/A
  • Revenue This Year
  • YHC $120.06
  • CING N/A
  • Revenue Next Year
  • YHC $72.42
  • CING N/A
  • P/E Ratio
  • YHC N/A
  • CING N/A
  • Revenue Growth
  • YHC 158.05
  • CING N/A
  • 52 Week Low
  • YHC $0.40
  • CING $1.80
  • 52 Week High
  • YHC $2.45
  • CING $20.83
  • Technical
  • Relative Strength Index (RSI)
  • YHC N/A
  • CING 41.44
  • Support Level
  • YHC N/A
  • CING $4.38
  • Resistance Level
  • YHC N/A
  • CING $5.03
  • Average True Range (ATR)
  • YHC 0.00
  • CING 0.40
  • MACD
  • YHC 0.00
  • CING -0.06
  • Stochastic Oscillator
  • YHC 0.00
  • CING 5.81

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: